查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601067

微生物組治療市場：依產品、治療領域、配方、來源、最終用途、分銷管道 - 2025-2030 年全球預測

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年微生物組治療市值為9.8802億美元，預計到2024年將達到11.1894億美元，複合年成長率為14.45%，預計到2030年將達到25.4245億美元。

微生物組療法是指利用活生物體和有針對性的營養策略來調節人類腸道微生物組以解決各種健康問題的治療方法。這些治療方法對於治療胃腸道疾病、代謝症候群、自體免疫疾病等至關重要，並且有可能擴展到心理健康和腫瘤學領域。對微生物組療法的需求源於人們對微生物組在維持健康和相關疾病增加中的重要作用的日益了解。最終用途涵蓋許多領域，包括製藥、機能性食品和生物技術。主要成長動力包括基因序列測定和診斷技術的進步、製藥公司投資的增加以及消費者對整體健康解決方案的興趣增加。隨著監管機構採用以微生物為基礎的解決方案框架，為創新產品提供更順暢的進入，一個顯著的機會將會出現。為了利用這些機會，相關人員應促進新研發項目的產學合作，並利用適應性試驗設計來加速臨床試驗過程。然而，嚴格的監管環境、人類微生物與宿主相互作用的複雜性以及高產品開發成本等挑戰可能會阻礙市場開拓。此外，由於微生物組研究標準化有限，產品功效可能不一致。克服這些障礙需要在個人化醫療方面進行深入創新，並開發強大且具成本效益的微生物組調控和分析平台。對開拓的細菌菌株和合成生物學的研究有可能帶來突破。市場正在從小眾發展為主流，這反映在創業投資興趣和策略夥伴關係關係的增加上，需要相關人員的敏捷性和遠見。因此，投資者和開發商將重點放在與老齡化相關的微生物組干預和腸腦軸治療等領域，以在快速擴張的微生物組治療領域中保持競爭力和相關性。

主要市場統計
基準年[2023] 98802萬美元
預測年份 [2024] 111,894 萬美元
預測年份 [2030] 25.4245億美元
複合年成長率（%） 14.45%

市場動態：揭示快速發展的微生物組治療市場的關鍵市場洞察

微生物組治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 與文明病盛行率增加
    • 微生物組研究和商業化的政府措施和資助
  • 市場限制因素
    • 微生物組療法產品回想的潛在風險
  • 市場機會
    • 使用微生物組療法管理女性荷爾蒙和生殖健康
    • 利用人工智慧擴大微生物組療法的投資
  • 市場挑戰
    • 與治療中微生物組資料收集和使用相關的倫理和隱私問題

波特的五力：駕馭微生物組治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解微生物組治療市場的外部影響

外部宏觀環境因素在塑造微生物組治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解微生物組治療市場的競爭格局

對微生物組治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣微生物治療市場供應商的績效評估

FPNV 定位矩陣是評估微生物組治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃微生物組治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，微生物組治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 與文明病盛行率增加
      • 政府對微生物組研究和商業化的承諾和資助
    • 抑制因素
      • 微生物組療法產品回想的潛在風險
    • 機會
      • 利用微生物療法促進女性荷爾蒙和生殖健康
      • 增加對基於人工智慧的微生物組治療的投資
    • 任務
      • 與微生物組資料的收集和治療使用相關的道德和隱私問題
  • 市場區隔分析
    • 產品：對慢性病針對性介入的微生物組療法的需求不斷成長
    • 治療領域：自體免疫疾病對微生物組療法的需求不斷增加，以減少發炎和調節免疫反應
    • 製劑：解決胃腸道疾病的口服製劑需求增加
    • 資料來源：正在進行的利用動物微生物組來了解腸腦軸和免疫調節的研究
    • 最終用途：用於學術創新的微生物組療法的不斷發展的前景
    • 分銷管道：微生物組療法擴大透過線上管道分銷。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章微生物組治療市場：依產品

  • 糞便微生物移植
  • 活體生物療法
  • 微生物醫學
  • 微生物生態系療法
  • 益生菌和益生元

第 7 章按治療領域分類的微生物組治療市場

  • 自體免疫疾病
  • 癌症
  • 胃腸道疾病
  • 感染疾病
  • 代謝紊亂
  • 神經系統疾病

第8章按處方分類的微生物組治療市場

  • 口服
  • 話題

第 9 章微生物組治療市場：依來源分類

  • 動物微生物組
  • 環境微生物組
  • 人類微生物組

第10章微生物組治療市場：依最終用途

  • 學術/研究機構
  • 醫院/診所

第11章微生物組治療市場：按分銷管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第12章美洲微生物組治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太微生物組治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲的微生物組治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Nexilico 和 Siolta Therapeutics 已達成合作，利用先進的微生物組療法來推進嬰兒 NEC 的治療。
    • Metagen Therapeutics 與 JSR Corporation 合作在日本建立 FMT 藥物生產設施
    • Seed Health 在全國 Target 商店推出益生菌，擴大零售業務
    • Pendulum Therapeutics 和 BiomeSense 宣布進行一項微生物組研究，使用 GutLab 系統持續監測 Akkermansia muciniphila。
    • Canvas Biosciences 融資 1250 萬美元，用於推進基於微生物組的免疫腫瘤治療
    • Biolog, Inc. 推出 PreBioM微孔盤來推進腸道微生物群的表徵。
    • Ceres Therapeutics 與雀巢健康科學合作，加強微生物組治療組合
    • Nature Awards 與 Seed Health 合作推出微生物組加速器解決方案
    • Ceres Therapeutics 加強 VOWST 並實現 SER-155 的 FDA 快速通道。
    • Ferring BV 與 PharmaBiome 合作開發以微生物組為基礎的胃腸道疾病治療方法
    • Persephone Biosciences 和 Ginkgo Bioworks 合作增強擬桿菌工程以促進治療開發
    • 創新團隊透過與微生物療法 MaaT Pharma 合作擴大規模
  • 戰略分析和建議
    • 恩特羅姆公司
    • XBiome有限公司
    • 輝凌公司
    • 穀神星醫藥科技股份有限公司

公司名單

  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring BV
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.
Product Code: MRR-ED54C46E807C

The Microbiome Therapeutics Market was valued at USD 988.02 million in 2023, expected to reach USD 1,118.94 million in 2024, and is projected to grow at a CAGR of 14.45%, to USD 2,542.45 million by 2030.

Microbiome therapeutics refer to treatments focused on modulating the human gut microbiota to address various health issues, utilizing live organisms or targeted nutritional strategies. These therapies are pivotal in treating conditions like gastrointestinal disorders, metabolic syndromes, and autoimmune diseases, with potential extensions into mental health and oncology. The necessity of microbiome therapeutics emerges from an increasing understanding of the microbiota's integral role in maintaining health, coupled with growing incidences of related ailments. Applications range from drugs to dietary interventions and supplements, and the end-use spans numerous sectors including pharmaceuticals, functional foods, and biotechnology. Key growth drivers include advancements in genetic sequencing and diagnostic technologies, increased investment from pharmaceutical companies, and a heightened consumer focus on holistic health solutions. Noteworthy opportunities arise from regulatory agencies adopting frameworks for microbiome-based solutions, enabling smoother entry for innovative products. To harness these opportunities, stakeholders should foster collaborations between academia and industry for novel R&D ventures and expedite clinical trial processes by leveraging adaptive trial designs. However, challenges such as stringent regulatory landscapes, the complexity of human microbiota-host interactions, and the high cost of product development can impede market progress. Moreover, limited standardization in microbiome research can lead to inconsistent product efficacy. Overcoming these barriers requires focused innovation in personalized medicine and development of robust, cost-effective platforms for microbiome modulation and analysis. Research into unexplored strains and synthetic biology holds potential for driving breakthroughs. The market is evolving from niche to mainstream, as reflected in growing venture capital interest and strategic partnerships, necessitating agility and foresight from stakeholders. Investors and developers should thus concentrate on areas like age-related microbiome interventions and gut-brain axis therapies to stay competitive and relevant in the fast-expanding microbiome therapeutics arena.

KEY MARKET STATISTICS
Base Year [2023] USD 988.02 million
Estimated Year [2024] USD 1,118.94 million
Forecast Year [2030] USD 2,542.45 million
CAGR (%) 14.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Microbiome Therapeutics Market

The Microbiome Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the prevalence of lifestyle-associated diseases
    • Government initiatives and funding for microbiome research and commercialization
  • Market Restraints
    • Potential risk of product recalls in microbiome therapeutics
  • Market Opportunities
    • Leveraging microbiome therapeutics for hormonal and reproductive health of women
    • Growing investment in AI-driven microbiome-based therapeutics
  • Market Challenges
    • Ethical and privacy concerns linked with microbiome data collection and usage in treatments

Porter's Five Forces: A Strategic Tool for Navigating the Microbiome Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Microbiome Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Microbiome Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Microbiome Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Microbiome Therapeutics Market

A detailed market share analysis in the Microbiome Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Microbiome Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Microbiome Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Microbiome Therapeutics Market

A strategic analysis of the Microbiome Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Microbiome Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alveolus Bio, Inc. by ResBiotic, AOBiome LLC, Assembly Biosciences, Inc., Axial Therapeutics, Inc., BioGaia AB, BiomeBank, EnteroBiotix Ltd, Enterome SA, Ferring B.V., Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., MaaT Pharma SA, Microba Life Sciences Limited, Microbiotica Ltd., MRM Health NV, NuBiyota, Osel, Inc., Pendulum Therapeutics, PharmaBiome AG, Pylum Biosciences, Seres Therapeutics, Inc., Servatus Limited, Siolta Therapeutics, Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome Life Sciences, Inc. by BlueDot LLC, and Xbiome Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Microbiome Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs, Microbiome Ecosystem Therapies, and Probiotics & Prebiotics.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Neurological Disorders.
  • Based on Formulation, market is studied across Oral and Topical.
  • Based on Source, market is studied across Animal Microbiome, Environmental Microbiome, and Human Microbiome.
  • Based on End-use, market is studied across Academic & Research Institutions and Hospitals & Clinics.
  • Based on Distribution Channel, market is studied across Offline and Online Pharmacies. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of lifestyle-associated diseases
      • 5.1.1.2. Government initiatives and funding for microbiome research and commercialization
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recalls in microbiome therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging microbiome therapeutics for hormonal and reproductive health of women
      • 5.1.3.2. Growing investment in AI-driven microbiome-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and privacy concerns linked with microbiome data collection and usage in treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Products: Rising need of microbiome therapeutics for targeted interventions in chronic diseases
    • 5.2.2. Therapeutic Area: Growing demand of microbiome therapeutics in autoimmune diseases for reducing inflammation and modulating immune responses
    • 5.2.3. Formulation: Growing demand for oral formulations to address gastrointestinal conditions
    • 5.2.4. Source: Ongoing research for the use of animal microbiomes in understanding the gut-brain axis and immune modulation
    • 5.2.5. End-use: The evolving landscape of microbiome therapeutics for academic innovations
    • 5.2.6. Distribution Channel: Thriving microbiome therapeutics distribution through online channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Microbiome Therapeutics Market, by Products

  • 6.1. Introduction
  • 6.2. Fecal Microbiota Transplantation
  • 6.3. Live-Biotherapeutics
  • 6.4. Microbiome Drugs
  • 6.5. Microbiome Ecosystem Therapies
  • 6.6. Probiotics & Prebiotics

7. Microbiome Therapeutics Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Gastrointestinal Disorders
  • 7.5. Infectious Diseases
  • 7.6. Metabolic Disorders
  • 7.7. Neurological Disorders

8. Microbiome Therapeutics Market, by Formulation

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Microbiome Therapeutics Market, by Source

  • 9.1. Introduction
  • 9.2. Animal Microbiome
  • 9.3. Environmental Microbiome
  • 9.4. Human Microbiome

10. Microbiome Therapeutics Market, by End-use

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Hospitals & Clinics

11. Microbiome Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Hospital Pharmacies
    • 11.2.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Americas Microbiome Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Microbiome Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Microbiome Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Nexilico and Siolta Therapeutics forge collaboration to advance treatments for infant NEC using advanced microbiome therapeutics
    • 15.3.2. Metagen Therapeutics partners with JSR Corporation to establish an FMT drug manufacturing facility in Japan
    • 15.3.3. Seed Health expands retail presence with launch of probiotics in target stores nationwide
    • 15.3.4. Pendulum Therapeutics and BiomeSense unveiled microbiome research with continuous monitoring of Akkermansia muciniphila using GutLab system
    • 15.3.5. Kanvas Biosciences raised USD 12.5 million to progress microbiome-based immuno-oncology therapies
    • 15.3.6. Biolog, Inc. unveiled PreBioM microplates to advance gut microbiome characterization
    • 15.3.7. Seres Therapeutics collaborates with Nestle Health Science to enhance its microbiome therapeutic portfolio
    • 15.3.8. Nature Awards and Seed Health unite to launch microbiome accelerator solutions
    • 15.3.9. Seres Therapeutics enhanced the VOWST and achieved FDA Fast Track for SER-155
    • 15.3.10. Ferring B.V. signs partnership with PharmaBiome for development of microbiome-based therapies for gastrointestinal conditions
    • 15.3.11. Persephone Biosciences and Ginkgo Bioworks collaborate to enhance Bacteroides engineering for therapeutics development
    • 15.3.12. Microbiome Therapeutics Innovation Group expanded by joining hands with MaaT Pharma
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Enterome SA
    • 15.4.2. Xbiome Co. Ltd.
    • 15.4.3. Ferring B.V.
    • 15.4.4. Seres Therapeutics, Inc.

Companies Mentioned

  • 1. Alveolus Bio, Inc. by ResBiotic
  • 2. AOBiome LLC
  • 3. Assembly Biosciences, Inc.
  • 4. Axial Therapeutics, Inc.
  • 5. BioGaia AB
  • 6. BiomeBank
  • 7. EnteroBiotix Ltd
  • 8. Enterome SA
  • 9. Ferring B.V.
  • 10. Intralytix, Inc.
  • 11. Kanvas Biosciences
  • 12. Locus Biosciences, Inc.
  • 13. MaaT Pharma SA
  • 14. Microba Life Sciences Limited
  • 15. Microbiotica Ltd.
  • 16. MRM Health NV
  • 17. NuBiyota
  • 18. Osel, Inc.
  • 19. Pendulum Therapeutics
  • 20. PharmaBiome AG
  • 21. Pylum Biosciences
  • 22. Seres Therapeutics, Inc.
  • 23. Servatus Limited
  • 24. Siolta Therapeutics
  • 25. Theriva Biologics, Inc.
  • 26. Vedanta Biosciences, Inc.
  • 27. Viome Life Sciences, Inc. by BlueDot LLC
  • 28. Xbiome Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. MICROBIOME THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MICROBIOME THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MICROBIOME THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MICROBIOME THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY LIVE-BIOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME ECOSYSTEM THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ANIMAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ENVIRONMENTAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HUMAN MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 327. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 328. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023